Price (delayed)
$0.9
Market cap
$56.49M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.73
Enterprise value
$133.98M
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug belapectin (formerly known as GR-MD-02) is a
There are no recent dividends present for GALT.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.